Users online: 1383    [ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2020, Volume : 13, Issue : 6
First page : ( 2920) Last page : ( 2924)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2020.00538.7

Estimation of Erythromycin and inducible Clindamycin Resistance in Saphylococcus aureus Isolated from Clinical Cases

Mtsher Amany Menam, Aziz Zahid Saadoon*

Department of Biology, College of Science, University of Misan, Maysan, Iraq

*Corresponding Author E-mail: zoonobiology@uomisan.edu.iq

Online published on 4 July, 2020.


Staphylococcus aureus is an important human pathogen. It is one of the common of both endemic and epidemic infections acquired in hospitals which result in substantial morbidity and mortality. S.aureus causing 50% or more of hospital-acquired S.aureus infections in several countries andcould cause life-threatening infections when mucosal or cutaneous barriers are broken. This study aims to determine the Erythromycin and inducible Clindamycin phenotypic and genotypic resistance, and the estimation prevalence of Erm A gene among the identified S.aureus in Maysan Province. A total of 300 samples were taken from patients suffering from different clinical infections during a period continued from October 2018 till March 2019. The samples were routinely cultivated and confirmed by using standard laboratory techniques where (103) were identified as S.aurues. The results of Erythromycin resistance and Clindamycin were 62 (60.1%) and 41 (39.8%) respectively. While the result of D-test appeared that 12 (11.6%) were positive to D-test whilst resistance to both Erythromycin and Clindamycin (R phenotype) was 15(14.5%)and sensitivity to both Erythromycin and Clindamycin (S phenotype) was 23 (22.5%). The result of Polymerase Chain Reaction (PCR) revealed that 100 (97%) of S.aureus were carried the ErmA gene. So the study went to concluded the high rates of prevalence of Erm A gene among identified S.aureus as comparing with phenotypic results which in turn lead to reduce the chance of available treatment especially through the intensive care units.



D-test, Erythromycin, Clindamycin and ErmA gene.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
597,093,815 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.